Impact of DNA patents on pharmacogenomics research and development: economic and policy issues

摘要: The science of pharmacogenetics and pharmacogenomics (or collectively PGx) has advanced rapidly in recent years, some technologies based on these developments have entered into use. It is notable that advances occurred parallel with related genetic testing, led by testing services for the diagnosis rare disorders share Mendelian patterns inheritance. However, a profusion patents nucleotide sequences (often termed ?gene patents?) to widespread concern disputes over intellectual property could hamper development diffusion technologies. This article outlines evidence from major empirical studies complex landscape diagnostic DNA United States Europe discusses traditional arguments favor against gene patenting PGx testing. also explores extent which concerns clinical genetics might be relevant PGx. We find although suggests many issues been overestimated or overemphasized, no dedicated published aspects Drug Dev Res 71: 485?491, 2010. © 2010 Wiley-Liss, Inc.